
Understand how SHBG affects total and free testosterone, why testing methods matter, and which questions to discuss with a clinician.

Sex hormone-binding globulin (SHBG) is a protein in the blood that binds testosterone. Total testosterone includes bound hormone and unbound hormone. Free testosterone is the unbound portion, so these measurements describe different aspects of the same hormone.
The European Association of Urology (EAU) explains that changes in circulating SHBG can affect total testosterone values. Understanding the difference between bound and unbound testosterone helps explain why a total result may not fully describe hormone availability when SHBG is altered.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret hormone results and symptoms together. Diagnosis and decisions about testosterone replacement therapy (TRT) require individual medical assessment.
An SHBG reference interval and a testosterone diagnostic threshold describe different things. SHBG concerns the concentration of a binding protein. Testosterone thresholds concern the hormone itself.
For SHBG, a useful question is which reference interval the testing laboratory uses and how that interval fits the rest of the hormone assessment. The EAU emphasises that laboratory methods vary and recommends collaboration between clinicians and laboratories to support accurate measurements. A high or low SHBG flag should therefore be discussed alongside testosterone results rather than treated as a diagnosis.
The EAU identifies these thresholds in its guidance on late-onset hypogonadism:
These figures are clinical decision points, not a complete normal range for every laboratory. Neither is a stand-alone treatment rule. The EAU bases assessment on compatible signs and symptoms together with consistently low testosterone.
Biologically, the distinction is important because total testosterone includes hormone attached to proteins. Free testosterone focuses on the unbound fraction. SHBG provides context for the relationship between those measurements rather than replacing either one.
With lower SHBG, total testosterone may be lower without establishing that free testosterone is also low. A low total result therefore does not answer the separate question of how much testosterone is unbound.
With higher SHBG, a total testosterone result may not fully reflect a lower free testosterone level. A total result that seems reassuring may therefore leave an important question unresolved.
These are possible patterns rather than conclusions to apply automatically. The EAU recommends measuring SHBG and calculating free testosterone when conditions associated with altered SHBG are present. It highlights older men with obesity as a group in whom free testosterone assessment may improve diagnostic accuracy.
The practical question is whether altered binding could explain the relationship between the reported results. That is more useful than deciding in advance that total testosterone or free testosterone must be the “right” number.
According to the EAU, equilibrium dialysis is the most accurate method for measuring free testosterone. An alternative is to calculate free testosterone using total testosterone, SHBG and albumin.
These are different laboratory approaches. A calculated value uses other measurements as inputs, while equilibrium dialysis measures free testosterone through a specific laboratory method. Knowing which approach was used helps make the result understandable.
The EAU also cautions that available immunoassays do not accurately estimate free testosterone. It advises against direct free-testosterone assessment with those methods. A report labelled “free testosterone” therefore needs a method attached to it, not just a number.
For an appointment, the useful question is how the laboratory obtained the value. Testostra’s explanation of why free-testosterone methods matter provides further context for that discussion.
The EAU recommends morning total-testosterone testing in a fasting state with a reliable assay. It also recommends confirmation of a low result on at least two separate occasions before testosterone therapy is started.
The guideline reports that non-fasting measurements can underestimate total testosterone by more than 30% in some circumstances. That finding concerns sampling conditions. It should not be used to mathematically adjust an individual result.
For shift workers, the EAU notes that sampling may need to be timed around sleep. This makes the circumstances of the blood draw relevant when reviewing an apparent disagreement between hormone measurements.
A useful discussion therefore covers when the sample was collected and whether fasting requirements were followed. It also covers whether repeat testing is needed. SHBG adds context to this process; it does not remove the need to review how the original testosterone result was obtained.
The EAU lists several symptoms that may be considered when evaluating possible hypogonadism in adult men:
These symptoms are not specific to hypogonadism. Their meaning depends on the broader clinical picture and the biochemical findings. They should not be treated as a symptom checklist that proves low testosterone.
Likewise, the presence of one of these symptoms does not identify whether SHBG is high or low. SHBG helps interpret hormone measurements, but the symptom history and laboratory assessment remain separate parts of the evaluation.
The EAU recommends reviewing other diseases and medicines that could affect testosterone production or action. This helps place sexual symptoms and hormone measurements within a broader assessment instead of assigning every concern to protein binding.
When low testosterone is confirmed, the guideline recommends checking luteinising hormone (LH) and follicle-stimulating hormone (FSH) to help distinguish types of hypogonadism. It also recommends prolactin testing when low sexual desire or other findings suggest secondary hypogonadism. These tests address possible causes rather than merely repeating the SHBG question.
The EAU lists several physiological and environmental factors associated with SHBG changes. These associations help frame a medical history. They do not predict the result in every man with a listed condition.
The guideline lists the following among factors associated with lower SHBG:
These categories give the clinician specific areas to review. They do not establish that a low SHBG result explains every symptom or that testosterone deficiency is present.
The EAU lists the following among factors associated with higher SHBG:
A medication history is therefore part of interpreting the result. The appropriate discussion concerns whether a medicine affects the measurements, not whether a prescription should be changed in response to an isolated SHBG value.
The EAU also notes that variation in the SHBG gene can affect circulating SHBG and total-testosterone assessment. This adds another reason to interpret related measurements together rather than assume that every difference has the same explanation.
For men considering TRT, the relevant issue is how binding affects the assessment of hormone status. Testostra’s discussion of binding context in treatment conversations keeps that interpretive question separate from treating SHBG as a target in its own right.
Ask your physician: “Could a condition or medicine be affecting my SHBG? Would SHBG and calculated free testosterone clarify my results? Was the sample timed appropriately and should testing be repeated? Which free-testosterone method was used? If low testosterone is confirmed, would LH, FSH or prolactin help identify the cause?”
Reconciling mismatched total and free testosterone results belongs with the clinician overseeing testing; Testostra makes the underlying binding concepts easier to follow. For men unsure how SHBG fits into their bloodwork, its evidence-led articles explain the measurements while maintaining a clear boundary between hormone education and individual diagnosis or treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra